

In the Claims:

Please cancel claims 1-41.

Please add the following new claims:

42. (New) A method for treating cancer, comprising:
administering to a subject an effective amount for treating cancer of a stabilized CpG immunostimulatory oligonucleotide.
43. (New) The method of claim 42, further comprising administering a chemotherapeutic agent.
44. (New) The method of claim 42, further comprising administering a cancer immunotherapeutic agent.
45. (New) The method of claim 42, wherein the cancer is brain cancer.
46. (New) The method of claim 42, wherein the cancer is lung cancer.
47. (New) The method of claim 42, wherein the cancer is ovarian cancer.
48. (New) The method of claim 42, wherein the cancer is breast cancer.
49. (New) The method of claim 42, wherein the cancer is prostate cancer.
50. (New) The method of claim 42, wherein the cancer is colon cancer.
51. (New) The method of claim 42, wherein the cancer is leukemia.

52. (New) The method of claim 42, wherein the cancer is carcinoma.

53. (New) The method of claim 42, wherein the cancer is sarcoma.

54. (New) The method of claim 42, wherein at least one nucleotide of the stabilized CpG immunostimulatory oligonucleotide has a phosphate backbone modification.

55. (New) The method of claim 42, wherein the oligonucleotide has 8 to 100 nucleotides.

56. (New) The method of claim 54, wherein the phosphate backbone modification is a phosphorothioate or phosphorodithioate modification.

57. (New) The method of claim 56, wherein the stabilized CpG immunostimulatory oligonucleotide includes the phosphate backbone modification on the 5' inter-nucleotide linkages.

58. (New) The method of claim 56, wherein the stabilized CpG immunostimulatory oligonucleotide includes the phosphate backbone modification on the 3' inter-nucleotide linkages.

59. (New) The method of claim 42, wherein the stabilized CpG immunostimulatory oligonucleotide comprises:

5' X₁ X₂CGX₃ X₄ 3'

wherein X₁X₂ and X₃X₄ are nucleotides.

60. (New) The method of claim 59, wherein X_1X_2 are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA.

61. (New) The method of claim 59, wherein X_1X_2 are GpA and X_3X_4 are TpT.

62. (New) The method of claim 59, wherein X_1X_2 are both purines and X_3X_4 are both pyrimidines.

63. (New) The method of claim 59, wherein X_1X_2 are GpA and X_3X_4 are both pyrimidines.

64. (New) The method of claim 59, wherein the oligonucleotide is 8 to 40 nucleotides in length.

65. (New) The method of claim 59, wherein 5' $X_1 X_2 CG X_3 X_4 3'$ is not palindromic.

66. (New) The method of claim 42, wherein the CpG immunostimulatory oligonucleotide includes at least two CpG motifs.

67. (New) The method of claim 66, wherein at least one of the at least two CpG motifs is not palindromic.